Results 31 to 40 of about 26,835 (181)
Journal of Advanced Research, 2023 Introduction: Acquired resistance to BRAF inhibitor vemurafenib is frequently observed in metastatic colorectal cancer (CRC), and it is a thorny issue that results in treatment failure.
Hui-Fang Hu +8 more
doaj +1 more source
Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]
, 2019 Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G +2 more
core +1 more source
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]
, 2015 The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva +36 more
core +2 more sources
Cancer Reports, 2023 Vemurafenib‐induced drug resistance in melanoma has been linked to receptor tyrosine kinase (RTK) upregulation. The MITF and SOX10 genes play roles as master regulators of melanocyte and melanoma development.
Tine Norman Alver +3 more
doaj +1 more source
MicroRNAs in melanoma development and resistance to target therapy [PDF]
, 2017 microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes.
Ascierto, Paolo Antonio +7 more
core +1 more source
Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. [PDF]
PLoS ONE, 2014 PURPOSE:Genetically-targeted therapies are both promising and costly advances in the field of oncology. Several treatments for metastatic melanoma with a mutation in the BRAF gene have been approved.
Patti Curl +4 more
doaj +1 more source
Türk Oftalmoloji Dergisi, 2020 Vemurafenib is a potent inhibitor of genetically activated BRAF, which is responsible for tumoral proliferation in cutaneous melanoma. A 56-year-old man receiving vemurafenib therapy presented with uveitis.
Hilal Eser Öztürk, Yüksel Süllü
doaj +1 more source
Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]
, 2018 The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P. +6 more
core +4 more sources
npj Precision Oncology, 2023 Combined BRAF + MEK inhibition is FDA approved for BRAF V600E-mutant solid tumors except for colorectal cancer. However, beyond MAPK mediated resistance several other mechanisms of resistance such as activation of CRAF, ARAF, MET, P13K/AKT/mTOR pathway ...
Blessie Elizabeth Nelson +15 more
doaj +1 more source
Cancer3D: understanding cancer mutations through protein structures. [PDF]
, 2014 The new era of cancer genomics is providing us with extensive knowledge of mutations and other alterations in cancer. The Cancer3D database at http://www.cancer3d.org gives an open and user-friendly way to analyze cancer missense mutations in the context
Godzik, Adam +2 more
core +1 more source